MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$3,587K
EPS
-$0.08
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-06-30
2025-03-31
Total revenues
-
-
69
-
Total revenues
86
117*
100
202
Research and development
817
2,683*
4,881
6,124
General and administrative
3,085
2,075*
2,730
3,275
Total operating expenses
3,902
4,757*
7,611
9,399
Operating loss
-3,816
-4,640*
-7,542
-9,197
Other income, net
231
-566*
1,795
594
Loss from continuing operations before income taxes
-3,585
-5,207*
-5,747
-8,603
Income tax expense
0
4*
0
-
Loss from continuing operations
-3,585
-5,211*
-5,747
-8,603
Product sales, net-Product
-
282*
-
-
General and administrative
-
5
-
-
Total operating expenses
-
5*
-
-
Income (loss) from discontinued operations, before taxes
-
277*
-
-
Income tax expense
-
0*
-
-
Loss from discontinued operations, net of income taxes
0
277*
-8
-8
Net loss
-3,585
-4,934*
-5,755
-8,611
Unrealized gaines on marketable securities, net of tax of 0
-2
15
-2
-20
Total other comprehensive gain
-2
15*
-2
-20
Comprehensive loss
-3,587
-4,919
-5,757
-8,631
Basic EPS
-0.08
-0.115
-0.13
-0.2
Diluted EPS
-0.08
-0.115
-0.13
-0.2
Basic Average Shares
42,768,000
42,872,000
42,759,000
42,673,000
Diluted Average Shares
42,768,000
42,872,000
42,759,000
42,673,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$3,587K
(58.44%↑ Y/Y)
Net loss
-$3,585K
(58.37%↑ Y/Y)
Total other
comprehensive gain
-$2K
(90.00%↑ Y/Y)
Loss from continuing
operations
-$3,585K
(58.33%↑ Y/Y)
Unrealized gaines on
marketable securities, net...
-$2K
(90.00%↑ Y/Y)
General and
administrative
$3,085K
(-5.80%↓ Y/Y)
Other segment items
$473K
(-53.90%↓ Y/Y)
Research and
development-Research And Development...
$194K
(-92.30%↓ Y/Y)
Research and
development-Repibresib VYN201
$150K
(-94.18%↓ Y/Y)
Loss from continuing
operations before income...
-$3,585K
(58.33%↑ Y/Y)
Other income, net
$231K
(-61.11%↓ Y/Y)
Total operating
expenses
$3,902K
(-58.48%↓ Y/Y)
Operating loss
-$3,816K
(58.51%↑ Y/Y)
Total revenues
$86K
(-57.43%↓ Y/Y)
Operating loss
-$3,816K
(58.51%↑ Y/Y)
Total operating
expenses
$3,902K
(-58.48%↓ Y/Y)
General and
administrative
$3,085K
(-5.80%↓ Y/Y)
Research and development
$817K
(-86.66%↓ Y/Y)
Buy us a coffee
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)